Clal Biotechnology Industries (CBI) Ltd.

www.cbi.co.il

Investment Company
Public Company

(TASE: CBI)

Tech Verticals Preferences

Biotechnology, Medical Devices, MedTech

General Data

Established	1998
Current Active Portfolio Companies:	8
Reg. Number:	abCDe

DESCRIPTION

Clal Biotechnology Industries (TASE: CBI) is Israel’s largest life sciences investment company. CBI is focused on identifying and supporting promising innovative ventures, developing proprietary solutions, addressing unmet medical needs with multibillion dollar market potential.
CBI invests in companies ranging from seed to maturity, both public and private. It applies diverse models of strategic cooperation, providing significant investments together with hands-on leadership and guidance.
CBI’s investments range from biotech and pharma to diagnostics and medical devices.

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
CCA4DB50-207A-E111-AC59-00155D32A403		Clal Biotechnology Industries (CBI) Ltd.
	Investment Arm	Cactus Acquisition Corp. 1	Clal Biotechnology Industries (CBI) Ltd.
	Subsidiary	Clal Life Sciences (CLS) LP	Clal Biotechnology Industries (CBI) Ltd.

REMARKS

Date	Remark
01/03/2010	Clal Biotechnology has acquired Biomedical Investments for $22m in cash, shares and warrants.

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	Azrieli Center, Triangle Bldg., 45th Floor
City	Tel Aviv
Country	Israel
Zip	6702301

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Cambridge, United States

City	Cambridge
State/Province	MA
Country	United States

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Assaf Segal	Acting CEO	Variance (Partner, Corporate Finance)
Ms. Shiran Manor	General Counsel
Mr. Avraham Fischer	Chairman	Infinity (Chairman)

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
May. 07, 2013	Third Public Offering	TASE	abCDe	abCDe
May. 30, 2011	Second Public Offering	TASE	abCDe	abCDe
May. 30, 2007	IPO	TASE	abCDe	abCDe

	FINANCIAL ROUNDS

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Apr. 09, 2017

abCDe

Other

Mar. 29, 2017

abCDe

PIPE

Sep. 10, 2009

abCDe

Other

Jan. 01, 1998

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Holding Company	abCDe	2019: Holds 47% of the company.
abC Defghij	Institutional Investor	abCDe	Holds 6.3% of the company.
abC Defghij	Investment Company	abCDe	Previously held 5.7%, 16/09/2009: sold 1% of their holdings for $4m. Now holds 0.13% of the company.
abC Defghij	High-Tech Company	abCDe	03/2017: Teva received more shares of CBI in exchange of its holdings in Gamida Cell. 2019: Holds 15% of the company.

	Acquisitions made by CBI

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	Sep. 02, 2013	abCDe
abC Defghij	Biomed...	Apr. 22, 2013	abCDe
abC Defghij	N/A	Mar. 01, 2010	abCDe

Preferences

Type of Financing	Equity
Stage Preferences	Initial Revenues,R&D,Revenue Growth,Seed
Phase Preferences	CE Approved,Clinical Trials,Discovery,FDA Approved,Phase I,Phase II,Phase III,Pre Clinical

SECTOR SEGMENTATION (By Number Of Companies)

Biomed

57%

Medical Devices

43%

	PORTFOLIO COMPANIES

Current Portfolio Companies (8)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Anchiano

Biomed

PIPE	29/06/2018	N/A	$22.9m
PIPE	29/07/2014	$7.4m	$7.5m
PIPE	13/11/2012	$3.95m	$4m	04/2018: Sold 8.8% of the company to Yelin Lapidot for $2.3m (NIS 8m). 09/2019: Now holds 19% of the company.
PIPE	21/04/2010	N/A	$3.3m
PIPE	03/06/2008	$1m	$3.65m
Buyout	11/04/2007	$2.95m	N/A	Bought out Yissum's equity in BioCancell

BioKine

Biomed

Third Round	06/03/2008	N/A	$1.5m	Holds 25% of the company
Second Round	10/01/2007	N/A	$0.6m
First Round	01/12/2003	N/A	$1m	Invested through CureTech

Capital Point

N/A

Investment in Fund

05/07/2021

N/A

CBI received 9.7% of Capital Point shares (plus cash) in exchange for 17% of eXIthera

Colospan

Third Round

27/09/2017

N/A

$7.7m

Elicio

Biomed

Second Round

31/08/2018

N/A

$26m

2019: Holds 35% of the company.

eXIthera

Biomed

Third Round	30/06/2019	N/A	$6m	07/2021: CBI sold 17% of eXIthera to Capital Point in exchange for $5.75m in cash and shares. Now holds 28% of the company.
Buyout	22/04/2013	N/A	N/A	Via the purchase of Access BridgeGap (changed to CBI USA) from Access Industries Holdings for $7.3m. 2019: Holds 45% of the company.

Pi-Cardia

Third Round	19/04/2020	N/A	$27m
Second Round	30/12/2015	N/A	$10m

Sight Diagnostics

Fourth Round	07/05/2020	N/A	$71m
First Round	01/04/2014	N/A	$6m

Current VC Fund Portfolio (1)

Fund Name

Fund Type

Date Announced

Amount

Remarks

Anatomy Medical...

Venture Capital Fund

01/12/2011

N/A

Holds 50% of the fund.

Exits (22)

Company Name	Exit Type	Date Announced	Amount	Remarks
abC Defghij	IPO	06/06/2010	abCDe
abC Defghij	Acquired	21/01/2021	abCDe	Novartis acquired all of Cadent’s outstanding stock in exchange for $210m upfront and up to $560 million in milestone payments.
abC Defghij	Acquired	11/07/2006	abCDe
abC Defghij	IPO	11/08/2000	abCDe	17/06/2009: Transferred to the NASDAQ Capital Market
abC Defghij	Holdings Sold	06/09/2016	abCDe
abC Defghij	IPO	13/08/2009	abCDe	Raised NIS 28m from the public.
abC Defghij	Acquired	27/03/2024	abCDe
abC Defghij	IPO	26/10/2018	abCDe	Including Green Shoe options ($3m); 05/2024: Delested from NASDQ.
abC Defghij (Other)	Acquired	18/05/2009	abCDe
abC Defghij	Acquired	02/09/2013	abCDe
abC Defghij	IPO	20/03/2014	abCDe
abC Defghij	Acquired	05/06/2006	abCDe
abC Defghij	Acquired	20/06/2018	abCDe
abC Defghij	Acquired	16/01/2020	abCDe	An all-stock transaction.
abC Defghij	IPO	27/06/2018	abCDe
abC Defghij	Merged	13/11/2003	abCDe
abC Defghij	Holdings Sold	01/12/2016	abCDe
abC Defghij	Holdings Sold		abCDe
abC Defghij	Acquired	21/06/2007	abCDe	May go up to $300m, based on milestones
abC Defghij	Acquired	18/07/2012	abCDe	Shares swap.
abC Defghij	Acquired	12/03/2012	abCDe	In cash.
abC Defghij	IPO	20/09/2000	abCDe	Delisted

Historic Portfolio (11)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Andromeda Biotech

Ceased to Operate

Biomed

Fourth Round	15/08/2012	$3.5m	$10m
Third Round - Extended	01/06/2011	$1.6m	$5.55m
Third Round	15/06/2010	$5.6m	$17.5m	Holds 84% of the company
Second Round - Extended	09/09/2009	$5.6m	$7.5m
First Round	01/04/2007	$1m	$1m

Arno (non-Israeli company)

Ceased to Operate

N/A

First Round

14/09/2010

N/A

Avraham Pharmaceuticals

Ceased to Operate

Biomed

Fourth Round	25/02/2016	N/A	$4m
Third Round	17/09/2014	N/A	$4.5m
Second Round	21/02/2013	N/A	$5.7m	Holds 19% of the company.
First Round	13/11/2011	$1m	$3m
Seed	14/04/2010	$1.5m	$9m

BioControl

Ceased to Operate

Other

01/03/2010

N/A

Transferred from Biomedical Investments; Holds 3% of the company

Braintact

Ceased to Operate

Biomed

First Round

01/02/2007

$0.25m

Holds 20% of the company

Campus Bio

Suspendeed Operations

First Round

01/05/2008

N/A

Holds 100% of the company.

CDx Laboratories

Written Off

N/A

First Round

01/10/1998

N/A

Wrote Off investment. Held 8% of the company (Down from 10% at time of investment)

CureTech

Ceased to Operate

Biomed

Fifth Round	17/09/2013	$2.6m	$3.8m
Buyout	02/09/2013	N/A	N/A	CBI realized the option to buy Teva's shares in CureTech. The payment will be the equivalent of 20% of CureTech's income from selling its products or the license to them, up to m44.5$.
Second Round	18/06/2003	$1.7m	$1.7m
First Round	01/01/2001	$1.6m	$2.4m
Seed	01/10/1995	$2.4m	$3m

Gili Medical

Ceased to Operate

Second Round	26/02/2015	N/A	N/A
Seed	14/04/2010	$0.08m	$0.16m

Iluten

Ceased to Operate

Biomed

Seed

13/01/2010

N/A

$0.23m

Holds 38% of the company.

VacciGuard

Ceased to Operate

Biomed

First Round

01/12/2010

N/A

$1.4m

Through Campus Bio

Last Updated:	abCDe
IVC Number:	abCDe